A Paragraph IV filing is not a legal emergency. It is a predictable business event built into the architecture of […]

Pharmaceutical value is not built exclusively in the laboratory. It is won and lost on the global chessboard of intellectual

KSR killed your obviousness defense. Amgen killed your functional claims. Here is the complete IP architecture for winning anyway, from

Part I — The Foundational Divide Why Biologic IP is a Different Discipline Entirely Before building any patent strategy, a

A brand-name drug loses 90% of its market share within 12 months of generic entry. That single data point explains

The IP landscape for small molecule drugs has never been harder to defend. R&D costs now exceed $2.23 billion per

Africa’s pharmaceutical market reached $27.65 billion in 2023 and is tracking toward $35 billion by 2032. South Africa alone is

The pharmaceutical R&D portfolio is the strategic core of the enterprise, a high-stakes arena where science, finance, and market dynamics

The patent system’s founding logic is straightforward: disclose an invention, receive a time-limited monopoly, then surrender it to the public.